CML Patient Update - July 25, 2007 Montreal, Ottawa, Toronto Canada

[Guest guest]

The following program will be presented in a format using teleconferencing and

web

casting technology. It will link up the Royal Hospital (Montreal) with

the Ottawa

General Hospital (Ottawa) and the Princess Margaret Hospital (Toronto) in

Canada.

Patients in each location will hear and see the presentations from the tri

locations. This is

probably the first time that this concept has been used with a patient

educational event.

If you are a patient located in any of these cities, please feel free to join

the growing

number of CML patients attending this event and similar events presented by the

CML

Society of Canada.

Looking forward to seeing everyone!

Cheers!

The Chronic Myelogenous Society of Canada

La société de Leucémie Myélogene chronique du Canada

CML Patient Update – Tri City Event

July 25, 2007

6:30 – 8:30 PM

Montreal Location Details: The Royal Hospital

J.S.L. Browne Amphitheatre

Ottawa Location Details: The Ottawa General Campus

Auditorium – 2nd floor

Toronto Location Details: The Princess Margaret Hospital

Auditorium – Room 604

Topics to be discussed as requested by our CML Society patients:

1. Effectiveness – Dr. Pierre Laneuville - Montreal

1. Gleevec or Sprycel: is one superior to the other?

2. Control of blood counts in the refractory patient

3. Choosing Sprycel vs. Tasigna in Gleevec refractory/resistant patients – is

there a reason

for one over the other?

4. IRIS update

5. Sprycel update (and perhaps Nilotinib update)

1. Side Effects – Dr. Isabelle Bence-Bruckler - Ottawa

1. Chronic effects of diarrhea

2. What are the causes of death in the rare CML patient who does not respond to

therapy

3. What should patients be expecting from CML and its treatment – performance

status,

quality of life

4. Drug interactions – theoretical versus practical

2. Other – Dr. Jeff Lipton - Toronto

1. The necessity of bone marrow testing on a yearly basis as per the Canadian or

NCCN

guidelines – clonal evolution and de novo clones

2. PCR variability in assays and when do you look at changing therapy – i.e.

increasing

Gleevec dose or drug switching

3. Treating Gleevec patients with IFN – is there a role

4. Can patients go back to Gleevec after therapy with Sprycel or Tasigna

5. Blood Gleevec level testing

6. Pregnancy and TKI's

In compliance with this grant, attendance will be taken, and evaluation forms

will be

provided, please do not forget to fill them in.